Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor Β1-associated osteoblastic changes
dc.contributor.author | Izumi, Kouji | en_US |
dc.contributor.author | Mizokami, Atsushi | en_US |
dc.contributor.author | Li, You Qiang | en_US |
dc.contributor.author | Narimoto, Kazutaka | en_US |
dc.contributor.author | Sugimoto, Kazuhiro | en_US |
dc.contributor.author | Kadono, Yoshifumi | en_US |
dc.contributor.author | Kitagawa, Yasuhide | en_US |
dc.contributor.author | Konaka, Hiroyuki | en_US |
dc.contributor.author | Koh, Eitetsu | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.contributor.author | Namiki, Mikio | en_US |
dc.date.accessioned | 2009-07-06T15:36:55Z | |
dc.date.available | 2010-10-05T18:27:29Z | en_US |
dc.date.issued | 2009-08-01 | en_US |
dc.identifier.citation | Izumi, Kouji; Mizokami, Atsushi; Li, You Qiang; Narimoto, Kazutaka; Sugimoto, Kazuhiro; Kadono, Yoshifumi; Kitagawa, Yasuhide; Konaka, Hiroyuki; Koh, Eitetsu; Keller, Evan T.; Namiki, Mikio (2009). "Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor Β1-associated osteoblastic changes." The Prostate 69(11): 1222-1234. <http://hdl.handle.net/2027.42/63038> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63038 | |
dc.description.abstract | BACKGROUND Tranilast is a therapeutic agent used in treatment of allergic diseases, although it has been reported to show anti-tumor effects on some cancer cells. To elucidate the effects of tranilast on prostate cancer, we investigated the mechanisms of its anti-tumor effect on prostate cancer. METHODS The anti-tumor effects and related mechanisms of tranilast were investigated both in vitro on prostate cancer cell lines and bone-derived stromal cells, and in vivo on severe combined immunodeficient (SCID) mice. We verified its clinical effect in patients with advanced hormone refractory prostate cancer (HRPC). RESULTS Tranilast inhibited the proliferation of LNCaP, LNCaP-SF, and PC-3 cells in a dose-dependent manner and growth of the tumor formed by inoculation of LNCaP-SF in the dorsal subcutis and in the tibia of castrated SCID mice. Flow cytometry and TUNEL assay revealed induction of cell cycle arrest and apoptosis by tranilast. Tranilast increased expression of proteins involved in induction of cell cycle arrest and apoptosis. Coculture with bone-derived stromal cells induced proliferation of LNCaP-SF cells. Tranilast also suppressed secretion of transforming growth factor Β1 (TGF-Β1) from bone-derived stromal cells, which induced their differentiation. Moreover, tranilast inhibited TGF-Β1-mediated differentiation of bone-derived stromal cells and LNCaP-SF cell migration induced by osteopontin. In the clinical investigation, PSA progression was inhibited in 4 of 16 patients with advanced HRPC. CONCLUSIONS These observations suggest that tranilast may be a useful therapeutic agent for treatment of HRPC via the direct inhibitory effect on cancer cells and suppression of TGF-Β1-associated osteoblastic changes in bone metastasis. Prostate 69:1222–1234, 2009. © 2009 Wiley-Liss, Inc. | en_US |
dc.format.extent | 434782 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor Β1-associated osteoblastic changes | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Urology, School of Medicine, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan ; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan. | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.contributor.affiliationother | Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan | en_US |
dc.identifier.pmid | 19434660 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63038/1/20975_ftp.pdf | |
dc.identifier.doi | 10.1002/pros.20975 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.